MUNDIPHARMA-SWITZERLAND - αποτελεσματα

pharmalogic ltd - heparin sodium - תמיסה להזרקה\אינפוזיה - heparin sodium 5000 iu/ml - heparin - heparin - treatment of thrombo-embolic disorders as deep vein thrombosis, acute arterial embolism or thrombosis, thrombophlebitis, pulmonary embolism , fat embolism. prophylaxis of deep vein thrombosis and thromboembolic events.

Ισραήλ - Εβραϊκά - Ministry of Health

אוקסיטוצין פאנפרמה זריקה 10 יחבלמל

pharmalogic ltd - oxytocin - תמיסה להזרקה\אינפוזיה - oxytocin 10 iu/ml - oxytocin - induction of labour for medical reasons stimulation of labour in hypotonic uterine inertia during caesarian section following the delivery ot the child prevention and treatment of postpartum uterine atony and haemorrhage.oxytocin injection may also be indicated in early stages of pregnancy as an adjunctive therapy for the management of incomplete inevitable or missed abortion.

Ισραήλ - Εβραϊκά - Ministry of Health

פיפרצילין טזובקטם פאנפרמה 4 גרם 500 מג

pharmalogic ltd - piperacillin as sodium; tazobactam as sodium - אבקה להכנת תמיסה לאינפוזיה - piperacillin as sodium 4 g; tazobactam as sodium 500 mg - tazobactam - tazobactam - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. pipoeracillin/tazobactam in combination with an aminoglycoside is indicated for suspected bacterial infections in neutropenic adults or children above 2 years . appencicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.

Ισραήλ - Εβραϊκά - Ministry of Health

פיפרצילין/ טזובקטם פאנפרמה 2 גרם/ 250 מ"ג

pharmalogic ltd - piperacillin as sodium 2 g; tazobactam as sodium 250 mg - powder for solution for infusion - tazobactam - antibiotic for the treatment of systemic and/or local bacterial infections caused by susceptible organisms. pipoeracillin/tazobactam in combination with an aminoglycoside is indicated for suspected bacterial infections in neutropenic adults or children above 2 years. appencicitis complicated by rupture with peritonitis and/or abscess formation in children aged 2-12 years.